In this talk, Dr. Jaclyn Hechtman will explore the utility of whole blood biopsy for profiling solid tumors, with a focus on the critical distinction between clonal hematopoiesis (CH) and tumor-derived mutations. By analyzing both plasma and Buffy coat, Caris Assure enables clinicians to more accurately identify tumor alterations, ensuring precise diagnosis and targeted treatment to improve patient outcomes.
